20. The Future of Drug Treatments

  1. Alfonso J. Cruz-Jentoft5 and
  2. John E. Morley6,7
  1. Francesco Landi1,
  2. Graziano Onder1 and
  3. Yves Rolland2,3,4

Published Online: 27 JUL 2012

DOI: 10.1002/9781118338032.ch20



How to Cite

Landi, F., Onder, G. and Rolland, Y. (2012) The Future of Drug Treatments, in Sarcopenia (eds A. J. Cruz-Jentoft and J. E. Morley), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/9781118338032.ch20

Editor Information

  1. 5

    Servicio de Geriatría, Hospital Universitario Ramón y Cajal, Madrid, Spain

  2. 6

    Division of Geriatric Medicine, Saint Louis University School of Medicine, St. Louis, MO, USA

  3. 7

    Division of Endocrinology, Saint Louis University School of Medicine, St. Louis, MO, USA

Author Information

  1. 1

    Department of Geriatrics – Policlinico A. Gemelli, Catholic University of the Sacred Heart, Rome, Italy

  2. 2

    INSERM Unit 1027, Toulouse, France

  3. 3

    Université de Toulouse, Toulouse, France

  4. 4

    Gérontopôle, Centre Hospitalier Universitaire de Toulouse, Toulouse, France

Publication History

  1. Published Online: 27 JUL 2012
  2. Published Print: 30 AUG 2012

ISBN Information

Print ISBN: 9781119975878

Online ISBN: 9781118338032



  • the future of drug treatments;
  • sarcopenia and negative outcomes, in therapeutic approaches;
  • lifestyle intervention, physical activity/nutrition impact on sarcopenia;
  • drugs, cardiovascular/hormone/metabolic on sarcopenia, biological plausibility;
  • ACE inhibitors on muscle function, and positive cardiovascular effects;
  • ACE inhibitors on skeletal muscles, evidence needed on sarcopenia;
  • ACE inhibitor in GH/IGF-1 modulation, and muscle loss prevention;
  • sarcopenia and statin effect on body composition, hypothetical;
  • anti-inflammatory and anabolic, GH on skeletal muscle function;
  • SARMs without side effects, promising in sarcopenia therapeutics


This chapter contains sections titled:

  • Introduction

  • Cardiovascular Drugs

  • Hormone Replacement

  • Metabolic Agents

  • β-Hydroxy β-Methylbutyrate

  • Other Possible Pharmacologic Approaches

  • Conclusions

  • References